Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Mavorixafor (CXCR4 inhibitor) in Severe Congenital Neutropenia. The expected timing is based on the latest available company guidance and may change.
4WARD trial. 6/27/24- Ph2 interim clinical data. 3/25/25- Full enrollment in Q3 or Q4 2025 w/ topline data in H2 2026. 6/10/25- Granted Fast Track Designation. 8/8/25- Trial ongoing. 11/5/25- Enrollment raised to 176, completion Q3 2026; sNDA and launch in 2028. 03/17/26:- 4WARD Ph3 chronic neutropenia trial enrollment on track for Q3 2026 completion; >100 sites active globally. 05/06/26:- 4WARD Phase 3 trial enrollment remains on track for Q3 2026 completion; now over 110 global sites active. 08/06/26:- 4WARD CRO transition; FDA meeting and enrollment update expected Q3 2026; topline data remains H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.